SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-040217
Filing Date
2023-05-16
Accepted
2023-05-16 10:30:26
Documents
14
Period of Report
2023-05-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea178564-8k_unicycive.htm   iXBRL 8-K 25095
2 PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED MAY 16, 2023 ea178564ex99-1_unicycive.htm EX-99.1 51151
3 GRAPHIC ex99-1_001.jpg GRAPHIC 16835
  Complete submission text file 0001213900-23-040217.txt   284381

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE uncy-20230516.xsd EX-101.SCH 2962
5 XBRL LABEL FILE uncy-20230516_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE uncy-20230516_pre.xml EX-101.PRE 22361
8 EXTRACTED XBRL INSTANCE DOCUMENT ea178564-8k_unicycive_htm.xml XML 3702
Mailing Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022
Business Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022 650-384-0642
Unicycive Therapeutics, Inc. (Filer) CIK: 0001766140 (see all company filings)

IRS No.: 813638692 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40582 | Film No.: 23925940
SIC: 2834 Pharmaceutical Preparations